AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32748572 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy; 8 sessions
Number of subjects: 32
Study 35217935 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related behaviours influenced by personal health schemas
Number of subjects: 66
Study 35217935 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions and health care provider advice aimed at behaviour modification
Number of subjects: 66
Study 32987199 — intervention group
Group type: COMPARATOR
Intervention: Asfotase alfa 0.5 mg/kg
Number of subjects: 27
Study 32987199 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa 2.0 mg/kg
Number of subjects: 27
Study 32987199 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa 3.0 mg/kg
Number of subjects: 27
Study 35560521 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (100% O2) pre-training
Number of subjects: 5
Study 35560521 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxia (21% O2) pre-training
Number of subjects: 5
Study 35560521 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (12% O2) to Normoxia (21% O2) pre-training
Number of subjects: 5
Study 35560521 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (100% O2) post-training
Number of subjects: 5
Study 35560521 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (12% O2) to Normoxia (21% O2) post-training
Number of subjects: 5
Study 35560521 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-training to Post-training
Number of subjects: 5
Study 34311460 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized counseling on diet and exercise from a trained dietitian
Number of subjects: 296
Study 34311460 — intervention group
Group type: COMPARATOR
Intervention: Group education on diet and exercise
Number of subjects: 296
Study 35671598 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral QLB with Dexmedetomidine 1 μg/kg (Group B)
Number of subjects: 70
Study 35671598 — intervention group
Group type: COMPARATOR
Intervention: Bilateral QLB with 0.25% Bupivacaine (Group A)
Number of subjects: 70
Study 32816351 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly methotrexate (MTX) 30 mg/m2 + vinblastine (VBL) 6 mg/m2
Number of subjects: 38
Study 33993800 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning message advising of potential harm to viewers
Number of subjects: 419
Study 33993800 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning message advising of potential harm to victims
Number of subjects: 419
Study 33993800 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning message about ability of police to track IP addresses
Number of subjects: 419
Study 33993800 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning message about possible illegality of pornography
Number of subjects: 419
Study 33993800 — intervention group
Group type: COMPARATOR
Intervention: Control group (no warning message)
Number of subjects: 419
Study 33513125 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-release hydrocortisone (DR-HC)
Number of subjects: 51
Study 33513125 — intervention group
Group type: COMPARATOR
Intervention: Conventional hydrocortisone treatment
Number of subjects: 51
Study 32320482 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 724
Study 33167760 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural odor inhalers (AromaStick®)
Number of subjects: 0
Study 33167760 — intervention group
Group type: COMPARATOR
Intervention: Red Bull®
Number of subjects: 0
Study 33167760 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stimulant)
Number of subjects: 0
Study 32170316 — intervention group
Group type: COMPARATOR
Intervention: Control (ConZnSO4) - corn-soybean meal-based diet + 100 ppm supplemental Zn from ZnSO4
Number of subjects: 32
Study 32170316 — intervention group
Group type: COMPARATOR
Intervention: Control PSZn (ConPSZn) - corn-soybean meal-based diet + 100 ppm supplemental Zn from Zn polysaccharide complex
Number of subjects: 32
Study 32170316 — intervention group
Group type: EXPERIMENTAL
Intervention: DDGS/ZnSO4 - corn-soybean meal-40% DDGS gestation diet and a 30% DDGS lactation diet, with 100 ppm supplemental Zn from ZnSO4
Number of subjects: 32
Study 32170316 — intervention group
Group type: EXPERIMENTAL
Intervention: DDGS/PSZn - corn-soybean meal-40% DDGS gestation diet and a 30% DDGS lactation diet, with 100 ppm supplemental Zn from Zn polysaccharide complex
Number of subjects: 32
Study 32170316 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal Zn losses - corn-soybean meal-based diets containing no supplemental Zn
Number of subjects: 32
Study 33517894 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care model with nurse care manager (NCM) support for medication treatment of OUD
Number of subjects: 170000
Study 33517894 — intervention group
Group type: COMPARATOR
Intervention: Usual Primary Care
Number of subjects: 170000
Study 32864990 — intervention group
Group type: EXPERIMENTAL
Intervention: MyDiaText™ (TM education and support application)
Number of subjects: 166
Study 32864990 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 166
Study 33482619 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest total cholesterol (TC) quartile
Number of subjects: 3741
Study 33482619 — intervention group
Group type: COMPARATOR
Intervention: Lowest total cholesterol (TC) quartile
Number of subjects: 3741
Study 32386127 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-exposed uninfected children (CHEU)
Number of subjects: 1380
Study 32386127 — intervention group
Group type: COMPARATOR
Intervention: HIV-unexposed children (CHU)
Number of subjects: 1380
Study 33952620 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 (1,800 mg/day fish oil)
Number of subjects: 43
Study 33952620 — intervention group
Group type: COMPARATOR
Intervention: Placebo (600 mg/day olive oil)
Number of subjects: 43
Study 32692245 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous spinal nerve posteromedial ramus destruction
Number of subjects: 118
Study 32692245 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 118
Study 35901367 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 854
Study 35238218 — intervention group
Group type: EXPERIMENTAL
Intervention: Streamlined consent approaches (six different types including one with a video before the appointment)
Number of subjects: 2618
Study 35238218 — intervention group
Group type: COMPARATOR
Intervention: Traditional consent approach (one type)
Number of subjects: 2618
Study 33306977 — intervention group
Group type: EXPERIMENTAL
Intervention: DLwn (deadlifts with straps based on without-straps 1-repetition max)
Number of subjects: 16
Study 33306977 — intervention group
Group type: COMPARATOR
Intervention: DLnn (deadlifts without straps)
Number of subjects: 16
Study 33306977 — intervention group
Group type: EXPERIMENTAL
Intervention: DLww (deadlifts with straps based on with-straps 1-repetition max)
Number of subjects: 16
Study 33306977 — intervention group
Group type: EXPERIMENTAL
Intervention: DLwn and DLww (deadlifts with straps)
Number of subjects: 16
Study 33306977 — intervention group
Group type: EXPERIMENTAL
Intervention: DLwn (deadlifts with straps)
Number of subjects: 16
Study 35363452 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1-g intravenous bolus)
Number of subjects: 9535
Study 35363452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9535
Study 34782054 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide and dummy ondansetron
Number of subjects: 33
Study 34782054 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron and dummy metoclopramide
Number of subjects: 33
Study 34782054 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide and ondansetron
Number of subjects: 33
Study 34782054 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dummy
Number of subjects: 33
Study 32349005 — intervention group
Group type: EXPERIMENTAL
Intervention: B125S5 (0.125% bupivacaine + 5 μg sufentanil in 15 mL)
Number of subjects: 169
Study 36264343 — intervention group
Group type: EXPERIMENTAL
Intervention: m-VISTA technique (test group, TG)
Number of subjects: 24
Study 36264343 — intervention group
Group type: COMPARATOR
Intervention: Coronally advanced flap (CAF) technique (control group, CG)
Number of subjects: 24
Study 33903052 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold therapy applied to the incision area after abdominal surgery
Number of subjects: 60
Study 33903052 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cold therapy)
Number of subjects: 60
Study 33903052 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold therapy
Number of subjects: 60
Study 35040866 — intervention group
Group type: EXPERIMENTAL
Intervention: No artificial sweeteners claim
Number of subjects: 2219
Study 35040866 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% Vitamin C claim
Number of subjects: 2219
Study 35040866 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% All Natural claim
Number of subjects: 2219
Study 35040866 — intervention group
Group type: COMPARATOR
Intervention: No claim (control group)
Number of subjects: 2219
Study 35040866 — intervention group
Group type: EXPERIMENTAL
Intervention: All claims
Number of subjects: 2219
Study 34043108 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline with heparin (3000 units to 500 ml of normal saline)
Number of subjects: 147
Study 34043108 — intervention group
Group type: COMPARATOR
Intervention: Normal saline without heparin
Number of subjects: 147
Study 33124987 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led web-based intervention including four short videos, an interactive scenario game, and a risk assessment tool.
Number of subjects: 578
Study 33124987 — intervention group
Group type: COMPARATOR
Intervention: Control group using an existing website promoting physical activities and healthy living.
Number of subjects: 578
Study 35759564 — intervention group
Group type: EXPERIMENTAL
Intervention: SONYA device stimulation
Number of subjects: 32
Study 35759564 — intervention group
Group type: COMPARATOR
Intervention: Placebo (false stimulation)
Number of subjects: 32
Study 32592861 — intervention group
Group type: EXPERIMENTAL
Intervention: bilateral TBS monotherapy
Number of subjects: 53
Study 32592861 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 53
Study 36315941 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (PT)
Number of subjects: 0
Study 36315941 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic partial meniscectomy
Number of subjects: 0
Study 33451721 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 563
Study 33451721 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg/metoclopramide 10 mg
Number of subjects: 563
Study 33451721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 563
Study 33199443 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus panitumumab
Number of subjects: 474
Study 33199443 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 474
Study 33199443 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of anti-EGFR inhibitors to the chemotherapy agent epirubicin
Number of subjects: 474
Study 33262195 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (rt-PA) (35-80 mg)
Number of subjects: 1473
Study 33262195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1473
Study 35319274 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD (2.5 mg):THC (0.035 mg/kg) ratio (1:1)
Number of subjects: 28
Study 35319274 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD (2.5 mg):THC (0.035 mg/kg) ratio (2:1)
Number of subjects: 28
Study 35319274 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD (2.5 mg):THC (0.035 mg/kg) ratio (3:1)
Number of subjects: 28
Study 33440084 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil (72 µg, four times daily)
Number of subjects: 326
Study 33440084 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil
Number of subjects: 326
Study 33440084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study 32471480 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR‐RT (Blood Flow Restriction Resistance Training)
Number of subjects: 30
Study 32471480 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 30
Study 34193105 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 34193105 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Cat Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 34193105 — intervention group
Group type: COMPARATOR
Intervention: Optimization of Stage 1 treatment
Number of subjects: 0
Study 34193105 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (optimization of Stage 1 treatment + addition of the other intervention)
Number of subjects: 0
Study 34618727 — intervention group
Group type: EXPERIMENTAL
Intervention: Presepsin guidance
Number of subjects: 656
Study 34618727 — intervention group
Group type: COMPARATOR
Intervention: Control group (international guidelines)
Number of subjects: 656
Study 33279459 — intervention group
Group type: COMPARATOR
Intervention: Normal Sleep (NS)
Number of subjects: 154
Study 33279459 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Restriction (SR)
Number of subjects: 154
Study 33279459 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD)
Number of subjects: 154
Study 34312449 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week complex, supervised rehabilitation protocol
Number of subjects: 51
Study 34312449 — intervention group
Group type: COMPARATOR
Intervention: Home exercise program alone
Number of subjects: 51
Study 32524499 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06881894 (6 mg single dose)
Number of subjects: 573
Study 32524499 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06881894 (multiple 6 mg doses)
Number of subjects: 573
Study 32524499 — intervention group
Group type: COMPARATOR
Intervention: pegfilgrastim-US (6 mg single dose)
Number of subjects: 573
Study 32524499 — intervention group
Group type: COMPARATOR
Intervention: pegfilgrastim-US (multiple 6 mg doses)
Number of subjects: 573
Study 32524499 — intervention group
Group type: COMPARATOR
Intervention: pegfilgrastim-EU (6 mg single dose)
Number of subjects: 573
Study 35235720 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole (2–4 mg/d for short-term studies; 1–4 mg/d for long-term studies)
Number of subjects: 831
Study 35235720 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Number of subjects: 831
Study 33653824 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 17160
Study 32520909 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) early infant diagnosis (EID)
Number of subjects: 9539
Study 32520909 — intervention group
Group type: COMPARATOR
Intervention: Laboratory-based early infant diagnosis (EID)
Number of subjects: 9539
Study 35969402 — intervention group
Group type: EXPERIMENTAL
Intervention: Casirivimab and Imdevimab 1200 mg IV
Number of subjects: 815
Study 35969402 — intervention group
Group type: EXPERIMENTAL
Intervention: Casirivimab and Imdevimab 2400 mg IV
Number of subjects: 815
Study 35969402 — intervention group
Group type: EXPERIMENTAL
Intervention: Casirivimab and Imdevimab 600 mg SC
Number of subjects: 815
Study 35969402 — intervention group
Group type: EXPERIMENTAL
Intervention: Casirivimab and Imdevimab 1200 mg SC
Number of subjects: 815
Study 35969402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 815
Study 33985877 — intervention group
Group type: EXPERIMENTAL
Intervention: General dental practitioners' willingness to repair loose retainers
Number of subjects: 71
Study 33985877 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience with orthodontic services
Number of subjects: 71
Study 33985877 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of third-order side effects of bonded retainers
Number of subjects: 71
Study 33985877 — intervention group
Group type: EXPERIMENTAL
Intervention: Justification for permanent retention
Number of subjects: 71
Study 33985877 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsibility for long-term supervision of fixed retainers
Number of subjects: 71
Study 33985877 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest in further training on orthodontic retention
Number of subjects: 71
Study 33985877 — intervention group
Group type: EXPERIMENTAL
Intervention: Appreciation for clinical guidelines
Number of subjects: 71
Study 33333490 — intervention group
Group type: EXPERIMENTAL
Intervention: Kettlebell exercises
Number of subjects: 10
Study 33166551 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrus Microstent (Ivantis, Inc) implantation
Number of subjects: 556
Study 33166551 — intervention group
Group type: COMPARATOR
Intervention: Cataract surgery alone
Number of subjects: 556
Study 34873344 — intervention group
Group type: EXPERIMENTAL
Intervention: ITCA 650
Number of subjects: 4156
Study 34873344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4156
Study 33844995 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab (1 mg/kg bodyweight) and durvalumab (20 mg/kg bodyweight) every 4 weeks for four doses, followed by maintenance intravenous durvalumab at the same dose and schedule for nine doses.
Number of subjects: 40
Study 33844995 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment with the same doses and schedules for tremelimumab and durvalumab.
Number of subjects: 40
Study 33844995 — intervention group
Group type: EXPERIMENTAL
Intervention: TMB higher than the median value of 8.3 mutations per Mb in retreated cohort.
Number of subjects: 40
Study 33091093 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated NCD-HTS
Number of subjects: 320
Study 36038485 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐µM Ca.I A23187 for 10 min
Number of subjects: 70
Study 36038485 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 70
Study 32037549 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 155 U
Number of subjects: 125
Study 32037549 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 74 U
Number of subjects: 125
Study 32037549 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intramuscular saline)
Number of subjects: 125
Study 36028326 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid Artery Stenting (CAS)
Number of subjects: 826
Study 36028326 — intervention group
Group type: COMPARATOR
Intervention: Carotid Endarterectomy (CEA)
Number of subjects: 826
Study 36028326 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite outcome of adjudicated stroke or incident symptoms
Number of subjects: 826
Study 36028326 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjudicated stroke events
Number of subjects: 826
Study 34338742 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct transfer to angiography suite (DTAS)
Number of subjects: 174
Study 34338742 — intervention group
Group type: COMPARATOR
Intervention: Conventional workflow
Number of subjects: 174
Study 32873114 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard PMR group (practiced PMR at home every day for two weeks)
Number of subjects: 100
Study 32873114 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (practiced PMR for two weeks with additional daily placebo treatment)
Number of subjects: 100
Study 34088583 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined higher levels of plasma vitamin C
Number of subjects: 0
Study 34426142 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 114
Study 34426142 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 114
Study 34426142 — intervention group
Group type: COMPARATOR
Intervention: Stretching (active control)
Number of subjects: 114
Study 34321049 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture technique for securing tracheal tube (TT)
Number of subjects: 17
Study 34321049 — intervention group
Group type: COMPARATOR
Intervention: Wilko tie technique for securing TT
Number of subjects: 17
Study 34321049 — intervention group
Group type: COMPARATOR
Intervention: Lark's foot tie technique for securing TT
Number of subjects: 17
Study 32195715 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand strength-focused exercise program (n = 26) from 2 to 6 weeks after injury
Number of subjects: 52
Study 32195715 — intervention group
Group type: COMPARATOR
Intervention: Finger range of motion exercises (Control group, n = 26)
Number of subjects: 52
Study 32195715 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand strength-focused exercise program (n = 26)
Number of subjects: 52
Study 35437025 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 50
Study 35437025 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 50
Study 34146354 — intervention group
Group type: EXPERIMENTAL
Intervention: Tutorial pointing to perilesional sun damage as a clue to pAK/BD (group A)
Number of subjects: 124
Study 34146354 — intervention group
Group type: COMPARATOR
Intervention: Tutorial not pointing to perilesional sun damage (group B)
Number of subjects: 124
Study 35360515 — intervention group
Group type: EXPERIMENTAL
Intervention: Task Balance Training Program (TBT program)
Number of subjects: 66
Study 35360515 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 32019222 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14, administered orally, twice daily for 12 weeks
Number of subjects: 66
Study 32019222 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered orally, twice daily for 12 weeks
Number of subjects: 66
Study 32019222 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14
Number of subjects: 66
Study 32019222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 34648913 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced RUTF dose (intervention arm)
Number of subjects: 516
Study 34648913 — intervention group
Group type: COMPARATOR
Intervention: Standard RUTF dose (control arm)
Number of subjects: 516
Study 34334434 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS
Number of subjects: 11